CA1212942A - Process for the preparation of oligosaccharide fractions having pharmaceutical properties by chemical degradation of heparin - Google Patents
Process for the preparation of oligosaccharide fractions having pharmaceutical properties by chemical degradation of heparinInfo
- Publication number
- CA1212942A CA1212942A CA000448827A CA448827A CA1212942A CA 1212942 A CA1212942 A CA 1212942A CA 000448827 A CA000448827 A CA 000448827A CA 448827 A CA448827 A CA 448827A CA 1212942 A CA1212942 A CA 1212942A
- Authority
- CA
- Canada
- Prior art keywords
- heparin
- moles
- preparation
- fractions
- cupric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960002897 heparin Drugs 0.000 title claims abstract description 37
- 229920000669 heparin Polymers 0.000 title claims abstract description 37
- 230000008569 process Effects 0.000 title claims abstract description 30
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 27
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000002144 chemical decomposition reaction Methods 0.000 title abstract description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241001558496 Talpa caeca Species 0.000 claims abstract description 29
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims abstract description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 5
- 229940076286 cupric acetate Drugs 0.000 claims abstract description 5
- 239000001632 sodium acetate Substances 0.000 claims abstract description 5
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 5
- 238000006731 degradation reaction Methods 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 12
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 230000002785 anti-thrombosis Effects 0.000 abstract description 11
- 230000014508 negative regulation of coagulation Effects 0.000 abstract description 9
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 238000011534 incubation Methods 0.000 abstract description 3
- 239000003146 anticoagulant agent Substances 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 11
- 229910021653 sulphate ion Inorganic materials 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001858 anti-Xa Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000000727 fraction Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229960003339 sodium phosphate Drugs 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- -1 DTA sodium salt Chemical class 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- KQNKJJBFUFKYFX-UHFFFAOYSA-N acetic acid;trihydrate Chemical compound O.O.O.CC(O)=O KQNKJJBFUFKYFX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT40021/83A IT1195497B (it) | 1983-03-08 | 1983-03-08 | Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina |
| IT40021A/83 | 1983-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1212942A true CA1212942A (en) | 1986-10-21 |
Family
ID=11246670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000448827A Expired CA1212942A (en) | 1983-03-08 | 1984-03-05 | Process for the preparation of oligosaccharide fractions having pharmaceutical properties by chemical degradation of heparin |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US4629699A (enExample) |
| EP (1) | EP0121067B1 (enExample) |
| JP (1) | JPS59187002A (enExample) |
| AT (1) | ATE26843T1 (enExample) |
| AU (1) | AU549885B2 (enExample) |
| CA (1) | CA1212942A (enExample) |
| DE (2) | DE3463386D1 (enExample) |
| IT (1) | IT1195497B (enExample) |
| ZA (1) | ZA841520B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1163772B (it) * | 1983-07-13 | 1987-04-08 | Baldacci Lab Spa | Oligosaccaridi eterogenei complessabili ed alfa-idosani ad attivita' terapeutica, procedimento per la loro preparazione e relative composizioni farmaceutiche |
| IT1208509B (it) * | 1985-03-13 | 1989-07-10 | Mediolanum Farmaceutici Srl | Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico. |
| IT1214609B (it) * | 1985-05-17 | 1990-01-18 | Opocrin Spa | Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono. |
| IT1213384B (it) * | 1986-11-24 | 1989-12-20 | Lab Derivati Organici Mediolan | Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare. |
| FR2614026B1 (fr) * | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| EP0337327A1 (en) * | 1988-04-09 | 1989-10-18 | Bioiberica, S.A. | Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin |
| IT1234508B (it) * | 1988-06-10 | 1992-05-19 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
| IT1234826B (it) * | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
| US5519010A (en) * | 1989-02-06 | 1996-05-21 | Taiho Pharmaceutical Co., Ltd. | Sulfated polysaccharide, pharmaceutically acceptable salt thereof, process for preparing same and medicament containing same as effective component |
| WO1991015217A1 (en) * | 1990-04-06 | 1991-10-17 | Washington University | Anticoagulant oligosaccharides |
| IT1243987B (it) * | 1990-10-29 | 1994-06-28 | Derivati Organici Lab | Procedimento per la preparazione di epossi-eparidi prodotti ottenuti ecomposizioni farmaceutiche che li contengono |
| US5280016A (en) * | 1991-03-29 | 1994-01-18 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| GB9206291D0 (en) * | 1992-03-23 | 1992-05-06 | Cancer Res Campaign Tech | Oligosaccharides having growth factor binding affinity |
| US5861382A (en) * | 1992-05-01 | 1999-01-19 | Yeda Research And Development Co. Ltd. | Methods for regulation of active TNF-α |
| US6750207B1 (en) * | 1992-05-01 | 2004-06-15 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
| EP1095657B1 (en) * | 1992-11-10 | 2007-01-10 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
| IT1264709B1 (it) * | 1993-07-12 | 1996-10-04 | Italfarmaco Spa | Derivati eparinici ad attivita' antimetastatica |
| US5763427A (en) * | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US5744457A (en) * | 1995-03-31 | 1998-04-28 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US6001820A (en) * | 1995-03-31 | 1999-12-14 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US5980865A (en) | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
| US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| AU754936B2 (en) * | 1996-11-27 | 2002-11-28 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound |
| CA2293595A1 (en) * | 1997-06-06 | 1998-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| AUPO888497A0 (en) * | 1997-09-01 | 1997-09-25 | Australian National University, The | Use of sulfated oligosaccharides as inhibitors of cardiovascular disease |
| US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
| AUPO976897A0 (en) * | 1997-10-14 | 1997-11-06 | Australian National University, The | Use of sulfated oligosaccharides in lowering blood triglyceride levels |
| US6235725B1 (en) | 1998-10-30 | 2001-05-22 | Baker Norton Pharmaceuticals, Inc. | Methods and compositions for the prevention of tolerance to medications |
| JP2003504428A (ja) * | 1999-06-30 | 2003-02-04 | ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド | クロット関連凝固因子を阻害するヘパリン組成物 |
| JP4585072B2 (ja) * | 2000-02-29 | 2010-11-24 | 扶桑薬品工業株式会社 | ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物 |
| AU2001291549A1 (en) * | 2000-09-08 | 2002-03-22 | Hamilton Civic Hospitals Research Development Inc. | Antithrombotic compositions |
| RU2212210C2 (ru) * | 2001-01-24 | 2003-09-20 | Кемеровская городская клиническая больница № 3 им. М.А. Подгорбунского | Способ лечения при обморожении |
| US7285536B2 (en) * | 2001-12-05 | 2007-10-23 | Yeda Research And Development Co., Ltd. | Anti-cancer therapeutic compounds |
| EP1518120A4 (en) | 2002-03-11 | 2008-08-13 | Momenta Pharmaceuticals Inc | ANALYSIS OF SULFATE POLYSACCHARIDES |
| US20040171819A1 (en) | 2002-10-10 | 2004-09-02 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| WO2005018564A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
| EP1582531A1 (en) * | 2004-03-24 | 2005-10-05 | Aventis Pharma S.A. | Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products |
| ITMI20042068A1 (it) * | 2004-10-29 | 2005-01-29 | Opocrin Spa | Nuovo uso di eparine a bassissimo peso molecolare |
| EP1792621B1 (en) | 2005-11-30 | 2012-04-04 | Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni" | Orally administrable heparin derivatives |
| US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
| ES2567079T3 (es) | 2007-11-02 | 2016-04-19 | Momenta Pharmaceuticals, Inc. | Composiciones de polisacáridos que no son anticoagulantes |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| US8186278B2 (en) * | 2008-08-04 | 2012-05-29 | Industrial Design Fabrication & Installation, Inc. | Gear switch for a conveyor assembly |
| ES2817779T3 (es) | 2010-01-19 | 2021-04-08 | Momenta Pharmaceuticals Inc | Evaluación de preparaciones de heparina |
| CN102985443B (zh) | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
| CA2795868A1 (en) | 2010-06-17 | 2011-12-22 | Momenta Pharmaceuticals, Inc. | Methods and compositions for modulating hair growth |
| US9068957B2 (en) | 2011-02-21 | 2015-06-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| JP2016520613A (ja) | 2013-05-28 | 2016-07-14 | モメンタ ファーマシューティカルズ インコーポレイテッド | 薬学的組成物 |
| CN106947004A (zh) * | 2017-03-02 | 2017-07-14 | 浙江大学 | 一种低分子量肝素的制备方法 |
| CN107090052A (zh) * | 2017-05-16 | 2017-08-25 | 浙江大学 | 一种低分子量果胶的制备方法 |
| US11066684B2 (en) | 2017-06-20 | 2021-07-20 | The Regents Of The University Of California | Production of bioactive oligosaccharides |
| WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
| CA3144968A1 (en) | 2019-07-09 | 2021-01-14 | Optimvia Llc | Methods for synthesizing anticoagulant polysaccharides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1083903B (it) * | 1977-08-09 | 1985-05-25 | Lobo Srl | Oligo-eteropolisaccaridi con attivita' eparinosimili,procedimento per il loro ottenimento e relative composizioni terapeutiche |
| FR2440376A1 (fr) * | 1978-11-06 | 1980-05-30 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
| CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
| JPS56120704A (en) * | 1980-01-28 | 1981-09-22 | Hepar Ind Inc | Method of obtaining low molecular weight heparin having heightened pharmacologic property* product manufactured thereby and its use |
| US4281108A (en) * | 1980-01-28 | 1981-07-28 | Hepar Industries, Inc. | Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained |
| US4351938A (en) * | 1980-05-19 | 1982-09-28 | Riker Laboratories, Inc. | Anticoagulant substance |
-
1983
- 1983-03-08 IT IT40021/83A patent/IT1195497B/it active
-
1984
- 1984-02-18 AT AT84101701T patent/ATE26843T1/de not_active IP Right Cessation
- 1984-02-18 DE DE8484101701T patent/DE3463386D1/de not_active Expired
- 1984-02-18 DE DE198484101701T patent/DE121067T1/de active Pending
- 1984-02-18 EP EP84101701A patent/EP0121067B1/en not_active Expired
- 1984-02-23 US US06/582,933 patent/US4629699A/en not_active Expired - Lifetime
- 1984-02-27 AU AU25093/84A patent/AU549885B2/en not_active Expired
- 1984-02-29 ZA ZA841520A patent/ZA841520B/xx unknown
- 1984-03-05 CA CA000448827A patent/CA1212942A/en not_active Expired
- 1984-03-07 JP JP59044787A patent/JPS59187002A/ja active Granted
-
1986
- 1986-10-21 US US06/921,332 patent/US4791195A/en not_active Expired - Lifetime
-
1988
- 1988-09-21 US US07/247,154 patent/US4933326A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE121067T1 (de) | 1985-01-17 |
| US4791195A (en) | 1988-12-13 |
| AU2509384A (en) | 1984-09-13 |
| IT8340021A1 (it) | 1984-09-08 |
| JPS59187002A (ja) | 1984-10-24 |
| EP0121067B1 (en) | 1987-04-29 |
| US4933326A (en) | 1990-06-12 |
| DE3463386D1 (en) | 1987-06-04 |
| EP0121067A1 (en) | 1984-10-10 |
| AU549885B2 (en) | 1986-02-20 |
| IT8340021A0 (it) | 1983-03-08 |
| IT1195497B (it) | 1988-10-19 |
| JPS6344765B2 (enExample) | 1988-09-06 |
| US4629699A (en) | 1986-12-16 |
| ATE26843T1 (de) | 1987-05-15 |
| ZA841520B (en) | 1984-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4629699A (en) | Process for the preparation of oligosaccharide fractions by degradation of heparin | |
| DE3102621C2 (enExample) | ||
| HU188657B (en) | Process for the preparation of anticoagulant mycopolysaccharides | |
| EP0557887B1 (en) | Polysaccharide derivatives of heparin, heparan sulphate, fraction and fragments thereof, process for their preparation and pharmaceutical compositions containing them | |
| AU2003300161B2 (en) | Heparin-derived polysaccharide mixtures, preparation thereof and pharmaceutical compositions containing same | |
| HU203565B (en) | Process for producing heparin, heparane-sulfat and dermatane-sulfat of small molecular mass and pharmaceutical compositions containing them as active components | |
| CA2189038A1 (en) | O-desulfated heparin derivatives, methods of making and uses thereof | |
| EP0243968B1 (en) | Diacetylrhein potassium salt and its therapeutical use in the treatment of arthritis | |
| EP0504645B1 (de) | Verwendung von sulfatierten Oligosacchariden zur Behandlung arteriosklerotischer Erkrankungen und zur Verhinderung der Restenosierung | |
| US5721357A (en) | Preparation of sulfated polysaccharides for treatment or prevention of thromboses | |
| EP0066908A1 (en) | New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions | |
| CZ293639B6 (cs) | Sacharidové deriváty a farmaceutický prostředek | |
| JP4695756B2 (ja) | 新規な五糖類、その製造法およびそれを含む医薬組成物 | |
| EP0986580B1 (en) | Oligosaccharide mixtures having antithrombotic activity | |
| RU2183638C2 (ru) | Углеводные производные, фармацевтическая композиция на их основе | |
| JPS6036492A (ja) | スルフエート置換したオリゴ糖類及びその製造方法 | |
| EP0101141A2 (en) | Process for manufacturing low molecular weight heparins by depolymerization of normal heparin | |
| EP0408770B1 (en) | New sulfated polysaccharide, pharmaceutically acceptable salts thereof, preparation thereof, and drug containing the same as active ingredient | |
| US3851057A (en) | Dextran derivatives for the reduction of blood lipids | |
| CA1307785C (en) | Oligosaccharide derivatives | |
| CA1312861C (en) | Heparin derivatives and low molecular weight heparin derivatives | |
| EP0811635B1 (en) | Intravascular membrane thickening inhibitor | |
| NZ207793A (en) | Preparation of oligosaccharide fractions from heparin | |
| US5011919A (en) | Modified heparins and obtention process | |
| GB2080809A (en) | Phenoxyisobutyrates of moroxydin and drugs containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |